Short Bowel Syndrome Pipeline: 18+ Companies Driving Innovation in Rare Gastrointestinal Disease Therapies | DelveInsight

The treatment landscape for Short Bowel Syndrome (SBS) is witnessing meaningful progress, led by innovators like VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, and PhaseBio Pharmaceuticals. These companies are advancing a range of therapeutic approaches, including GLP-2 analogs, hormone-based therapies, and microbiome-targeted solutions, aimed at enhancing nutrient absorption, reducing parenteral support dependence, and improving patient outcomes.

DelveInsight's "Short Bowel Syndrome Pipeline Insight, 2025" provides a detailed analysis of the current R&D scenario and future outlook for SBS therapeutics. The report offers in-depth coverage of the disease landscape, treatment strategies, and a comprehensive pipeline review from preclinical to late-stage developments. It highlights mechanisms of action, clinical trial progress, regulatory milestones, and strategic developments, including licensing deals, designations, and funding.

The SBS pipeline report delivers a 360° overview of emerging drugs by development phase, molecule type, route of administration, and therapeutic targets-helping stakeholders identify key opportunities, competitive threats, and strategic collaborations in this rare but high-need market.
Key Takeaways from the Short Bowel Syndrome Pipeline Report
• DelveInsight's short bowel syndrome pipeline analysis depicts a strong space with 18+ active players working to develop 20+ pipeline drugs for short bowel syndrome treatment.
• The leading short bowel syndrome companies include VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others are evaluating their lead assets to improve the short bowel syndrome treatment landscape.
• Key short bowel syndrome pipeline therapies in various stages of development include Apraglutide, Glepaglutide, Vurolenatide, HM15912, NM-002, BioChaperone GLP-2, GLP2-ELP, Research programme: regenerative therapeutics, SEFA-6179, and others.
• In April 2025, Ironwood Pharmaceuticals (Nasdaq: IRWD) announced that the FDA requires a confirmatory Phase III trial for apraglutide to seek approval for short bowel syndrome (SBS) patients with intestinal failure. While advancing the therapy, Ironwood has enlisted Goldman Sachs to explore strategic alternatives to maximize stockholder value.
• In April 2025, Crofelemer, a plant-based anti-secretory drug, received Orphan Drug Designation from the FDA and EMA for short bowel syndrome (SBS) and microvillus inclusion disease (MVID). It is being evaluated as a potential treatment for managing intestinal failure in these patients.
• In December 2024, Zealand Pharma A/S (Nasdaq: ZEAL) announced that the FDA issued a Complete Response Letter (CRL) for its NDA for glepaglutide, a long-acting GLP-2 analog for treating short bowel syndrome (SBS) and intestinal failure (IF). The FDA requires additional clinical data, and Zealand plans to start a Phase III trial in 2025 to support resubmission.

Request a sample and discover the recent breakthroughs happening in the short bowel syndrome pipeline landscape @ https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Short Bowel Syndrome Overview
Short Bowel Syndrome (SBS) in adults is typically defined as having less than 180-200 centimeters of functional small intestine remaining, compared to a normal length of 275-850 cm, resulting in the need for nutritional and fluid supplementation. SBS is considered a form of intestinal failure. While rare, some infants are born with a congenitally short small intestine, often associated with intestinal malrotation, though the precise cause remains unclear. In most cases, SBS develops after surgical removal of a portion of the small intestine, performed to treat conditions such as bowel injury, disease, or congenital defects. In neonates, SBS most often follows surgery for necrotizing enterocolitis, a serious condition involving the destruction of intestinal tissue.

Find out more about short bowel syndrome medication @ https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Short Bowel Syndrome Treatment Analysis: Drug Profile
Glepaglutide: Zealand Pharma
Glepaglutide is a long-acting glucagon-like peptide-2 (GLP-2) analog being developed by Zealand Pharma for the treatment of Short Bowel Syndrome (SBS). Formulated as a liquid for subcutaneous delivery via autoinjector, it is designed to reduce or potentially eliminate the need for parenteral support in SBS patients. The therapy is currently in Phase III clinical development.

Learn more about the novel and emerging short bowel syndrome pipeline therapies @ https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Short Bowel Syndrome Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intravenous

By Molecule Type
• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Scope of the Short Bowel Syndrome Pipeline Report
• Coverage: Global
• Key Short Bowel Syndrome Companies: VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.
• Key Short Bowel Syndrome Pipeline Therapies: Apraglutide, Glepaglutide, Vurolenatide, HM15912, NM-002, BioChaperone GLP-2, GLP2-ELP, Research programme: regenerative therapeutics, SEFA-6179, and others.

Dive deep into rich insights for drugs used for short bowel syndrome treatment; visit @ https://www.delveinsight.com/report-store/heart-failure-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Short Bowel Syndrome Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Short Bowel Syndrome Pipeline Therapeutics
6. Short Bowel Syndrome Pipeline: Late-Stage Products (Phase III)
7. Short Bowel Syndrome Pipeline: Mid-Stage Products (Phase II)
8. Short Bowel Syndrome Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.